Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs
  • M&A / Deals

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
Next: BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

Related Stories

  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • M&A / Deals

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

pharminent June 1, 2026
  • M&A / Deals

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

pharminent June 1, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.